Lisa A. Jackson, MD, MPH, is an internist and infectious disease epidemiologist who has conducted clinical and epidemiologic studies of vaccine safety and efficacy since 1991. Dr. Jackson is the Kaiser Permanente Washington Health Research Institute (KPWHRI) principal investigator (PI) for the Vaccine Safety Datalink Project sponsored by the Centers for Disease Control and Prevention (CDC). She is also PI of the KPWHRI Vaccine and Treatment Evaluation Unit network site—one of nine network sites that the National Institutes of Health sponsors.
Dr. Jackson has written more than 200 peer-reviewed publications and 14 book chapters. She is a past member of the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee and the National Vaccine Program Office’s National Vaccine Advisory Committee.
After receiving her medical degree from the University of Virginia School of Medicine, in Charlottesville, Dr. Jackson earned her Master of Public Health (MPH) degree at the University of Washington (UW) School of Public Health. She completed her internal medicine residency training at the UW School of Medicine and served as an epidemic intelligence officer and preventive medicine resident at the CDC.
Vaccine safety; influenza vaccine effectiveness in the elderly; methodologic issues in vaccine effectiveness evaluations; pneumococcal polysaccharide vaccine effectiveness; pneumococcal conjugate vaccine immunogenicity in the elderly; epidemiology of E. coli bacteremia; epidemiology of community-acquired pneumonia
Zimmerman RK, Nowalk MP, Chung J, Jackson ML, Jackson LA, Petrie JG, Monto AS, McLean HQ, Belongia EA, Gaglani M, Murthy K, Fry AM, Flannery B. 2014-2015 influenza vaccine effectiveness in the United States by vaccine type. Clin Infect Dis. 2016 Dec 15;63(12):1564-1573. Epub 2016 Oct 4. PubMed
Flannery B, Zimmerman RK, Gubareva LV, Garten RJ, Chung JR, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Ohmit SE, Belongia EA, McLean HQ, Gaglani M, Piedra PA, Mishin VP, Chesnokov AP, Spencer S, Thaker SN, Barnes JR, Foust A, Sessions W, Xu X, Katz J, Fry AM. Enhanced genetic characterization of influenza A(H3N2) viruses and vaccine effectiveness by genetic group, 2014-2015. J Infect Dis. 2016 Oct 1;214(7):1010-9. doi: 10.1093/infdis/jiw181. Epub 2016 May 6. PubMed
Duffy J, Weintraub E, Hambidge SJ, Jackson LA, Kharbanda EO, Klein NP, Lee GM, Marcy SM, Nakasato CC, Naleway A, Omer SB, Vellozzi C, DeStefano F. Febrile seizure risk after vaccination in children 6 to 23 months. ediatrics. 2016 Jul;138(1). pii: e20160320. doi: 10.1542/peds.2016-0320. Epub 2016 Jun 6. PubMed
Gaglani M, Pruszynski J, Murthy K, Clipper L, Robertson A, Reis M, Chung JR, Piedra PA, Avadhanula V, Nowalk MP, Zimmerman RK, Jackson ML, Jackson LA, Petrie JG, Ohmit SE, Monto AS, McLean HQ, Belongia EA, Fry AM, Flannery B. Influenza vaccine effectiveness against the 2009 pandemic A(H1N1) virus differed by vaccine type during 2013-14 in the United States. J Infect Dis. 2016 May 15;213(10):1546-56. doi: 10.1093/infdis/jiv577. Epub 2016 Jan 6. PubMed
Groom HC, Henninger ML, Smith N, Koppolu P, Cheetham TC, Glanz JM, Hambidge SJ, Jackson LA, Kharbanda EO, Klein NP, McCarthy NL, Nordin JD, Weintraub ES, Naleway AL. Influenza vaccination during pregnancy: influenza seasons 2002-2012, Vaccine Safety Datalink. Am J Prev Med. 2016 Apr;50(4):480-8. doi: 10.1016/j.amepre.2015.08.017. Epub 2015 Oct 31. PubMed
Thompson MG, Clippard J, Petrie JG, Jackson ML, McLean HQ, Gaglani M, Reis EC, Flannery B, Monto AS, Jackson L, Belongia EA, Murthy K, Zimmerman RK, Thaker S, Fry AM. Influenza vaccine effectiveness for fully and partially vaccinated children 6 months to 8 years old during 2011-2012 and 2012-2013: the importance of two priming doses. Pediatr Infect Dis J. 2016 Mar;35(3):299-308. doi: 10.1097/INF.0000000000001006. PubMed
Chung JR, Flannery B, Thompson MG, Gaglani M, Jackson ML, Monto AS, Nowalk MP, Talbot HK, Treanor JJ, Belongia EA, Murthy K, Jackson LA, Petrie JG, Zimmerman RK, Griffin MR, McLean HQ, Fry AM. Seasonal effectiveness of live attenuated and inactivated influenza vaccine. Pediatrics. 2016 Feb;137(2):e20153279. doi: 10.1542/peds.2015-3279. Epub 2016 Jan 5. PubMed
Naleway AL, Crane B, Smith N, Daley MF, Donahue J, Gee J, Greene SK, Harrington T, Jackson LA, Klein NP, Tseng HF, Vellozzi C, Weintraub ES; Vaccine Safety Datalink. Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008-2011. Vaccine. 2016 Jan 2;34(1):167-71. doi: 10.1016/j.vaccine.2015.10.006. Epub 2015 Nov 6. PubMed
Zimmerman RK, Balasubramani GK, Nowalk MP, Eng H, Urbanski L, Jackson ML, Jackson LA, McLean HQ, Belongia EA, Monto AS, Malosh RE, Gaglani M, Clipper L, Flannery B, Wisniewski SR. Classification and Regression Tree (CART) analysis to predict influenza in primary care patients. BMC Infect Dis. 2016 Sep 22;16(1):503. PubMed
Chen WH, Jackson LA, Edwards KM, Keitel WA, Hill H, Noah DL, Creech CB, Patel SM, Mangal B, Kotloff KL. Persistence of antibody to influenza A/H5N1 vaccine virus: impact of AS03 adjuvant. Clin Vaccine Immunol. 2015 Nov 11. pii: CVI.00475-15. [Epub ahead of print]. PubMed
From clinical trials to technical support, Dr. Rita Mangione-Smith describes how Kaiser Permanente Washington researchers are fighting the novel coronavirus.
On March 16, 4 volunteers received an injection of an mRNA vaccine for COVID-19 in an NIH-funded trial in Seattle.
Associated Press, Mar 16, 2020
Dr. Lisa A. Jackson leads national trial to explore improving immune responses to the vaccine.
Read it in News and Events.
Seattle Times, Feb. 26, 2020